Browsing: Kenya Pharmacy and Poisons Board (PPB)

Kenya’s Pharmacy and Poisons Board (PPB) has approved the use of a prescription drug manufactured by Janssen, one of the pharmaceutical companies of Johnson & Johnson, for the treatment of prostate cancer. The local pharmaceuticals regulator has approved the use of Janssen’s once-daily medication ZYTIGA® (abiraterone acetate) for the treatment of metastatic castration-resistant prostate cancer ahead of a chemotherapy regime. The approval is expected to help boost ongoing efforts to minimise existing barriers to cancer care access in Kenya. Since its first approval in the U.S. in 2011, ZYTIGA® has been approved in combination with prednisone or prednisolone, in 105 countries.

Kenya’s Pharmacy and Poisons Board (PPB) has approved the use of a prescription drug manufactured by Janssen, one of the pharmaceutical companies of Johnson & Johnson, for the treatment of prostate cancer.

The local pharmaceuticals regulator has approved the use of Janssen’s once-daily medication ZYTIGA® (abiraterone acetate) for the treatment of metastatic castration-resistant prostate cancer ahead of a chemotherapy regime.

The approval is expected to help boost ongoing efforts to minimise existing barriers to cancer care access in Kenya.

READ ALSO:Kenya: Prostate cancer patients to get cheaper drugs

The prescription only innovator (non generic) oncological management drug is distributed locally by Janssen Kenya as part of the global pharmaceutical firm’s commitment to enhance access of essential drugs.

Speaking, when he confirmed the recent approval, Janssen Kenya Country Manager Marseille Onyango said prior to the approval, ZYTIGA had only been licensed for treatment of advanced prostate cancer cases post chemotherapy.…